We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
17 hedge funds and large institutions have $1.04M invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
52% more capital invested
Capital invested by funds: $684K → $1.04M (+$355K)
6% more funds holding
Funds holding: 16 → 17 (+1)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$50.1K |
| 2 |
BlackRock
New York
|
+$1.75K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$337 |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$248 |
| 5 |
Morgan Stanley
New York
|
+$144 |